HK1148435A1 - Oxadiazoanthracene compounds for the treatment of diabetes - Google Patents

Oxadiazoanthracene compounds for the treatment of diabetes

Info

Publication number
HK1148435A1
HK1148435A1 HK11102525.7A HK11102525A HK1148435A1 HK 1148435 A1 HK1148435 A1 HK 1148435A1 HK 11102525 A HK11102525 A HK 11102525A HK 1148435 A1 HK1148435 A1 HK 1148435A1
Authority
HK
Hong Kong
Prior art keywords
oxadiazoanthracene
diabetes
compounds
treatment
oxadiazoanthracene compounds
Prior art date
Application number
HK11102525.7A
Other languages
English (en)
Chinese (zh)
Inventor
‧米加裡
‧波裡塞蒂
‧約庫姆
‧桑托什
‧居澤爾
‧貝梅
‧戴維斯
Original Assignee
轉化技術製藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 轉化技術製藥有限責任公司 filed Critical 轉化技術製藥有限責任公司
Publication of HK1148435A1 publication Critical patent/HK1148435A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK11102525.7A 2008-03-07 2011-03-14 Oxadiazoanthracene compounds for the treatment of diabetes HK1148435A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
PCT/US2009/036333 WO2009111700A2 (en) 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes

Publications (1)

Publication Number Publication Date
HK1148435A1 true HK1148435A1 (en) 2011-09-09

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11102525.7A HK1148435A1 (en) 2008-03-07 2011-03-14 Oxadiazoanthracene compounds for the treatment of diabetes

Country Status (18)

Country Link
US (7) US7727983B2 (ko)
EP (1) EP2262364B1 (ko)
JP (1) JP5382952B2 (ko)
KR (1) KR101616737B1 (ko)
CN (1) CN101959405B (ko)
AU (1) AU2009221722B2 (ko)
BR (1) BRPI0910282A2 (ko)
CA (1) CA2716664C (ko)
DK (1) DK2262364T3 (ko)
EA (1) EA018225B1 (ko)
ES (1) ES2567451T3 (ko)
HK (1) HK1148435A1 (ko)
IL (1) IL207570A (ko)
MA (1) MA32175B1 (ko)
MX (1) MX2010009752A (ko)
NZ (1) NZ587343A (ko)
WO (1) WO2009111700A2 (ko)
ZA (1) ZA201006367B (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111700A2 (en) 2008-03-07 2009-09-11 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
WO2010114824A1 (en) 2009-03-30 2010-10-07 Transtech Pharma Inc Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CA2822017C (en) 2010-12-23 2015-04-07 Pfizer Inc. Glucagon receptor modulators
WO2012096824A1 (en) 2011-01-12 2012-07-19 Transtech Pharma, Inc. Phenylglyoxylic acid derivatives and their preparation and use
EP2673260B1 (en) 2011-02-08 2016-08-17 Pfizer Inc Glucagon receptor modulator
CA2841237C (en) 2011-07-22 2016-05-10 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG11201405353VA (en) * 2012-03-22 2014-09-26 Transtech Pharma Llc Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
ES2687083T3 (es) * 2013-01-17 2018-10-23 Vtv Therapeutics Llc Combinaciones de un agonista del GLPR1 y metformina y el uso de estos para el tratamiento de la diabetes tipo 2 y otros trastornos
KR102564946B1 (ko) * 2014-07-25 2023-08-08 리셉토스 엘엘씨 신규 glp-1 수용체 조절제
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019103060A1 (ja) * 2017-11-22 2019-05-31 第一三共株式会社 縮合三環化合物
MX2020008387A (es) 2018-05-08 2020-12-11 Vtv Therapeutics Llc Usos terapeuticos de agonistas glp1r.
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4159719A4 (en) * 2020-05-28 2024-07-17 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd METHOD FOR PREPARING METHYL PROPANOATE DIACID SALT (S)-2-AMINO-3-(4-(2,3-DIMETHYLPYRIDINE-4-YL)PHENYL)
EP4159737A1 (en) * 2020-05-28 2023-04-05 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Method for preparing glp-1 receptor agonist free base
CN115884969A (zh) 2020-09-01 2023-03-31 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022078152A1 (zh) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
CA3200245A1 (en) 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
EP4317142A1 (en) 2021-03-22 2024-02-07 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
JPWO2022202864A1 (ko) 2021-03-24 2022-09-29
CN117500808A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
CR20230611A (es) 2021-06-24 2024-02-19 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista del receptor de glp-1 y composición y uso del mismo.
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
ATE236115T1 (de) * 1995-10-06 2003-04-15 Ligand Pharm Inc Dimer-selektive rxr modulatoren und verfahren zu ihrer verwendung
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
CN1215059C (zh) * 1999-12-03 2005-08-17 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
EP1125925A1 (en) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US20050222036A1 (en) * 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
WO2004085403A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
WO2009111700A2 (en) * 2008-03-07 2009-09-11 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
US8501982B2 (en) 2010-06-09 2013-08-06 Receptos, Inc. GLP-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
US7790714B2 (en) 2010-09-07
US8933222B2 (en) 2015-01-13
EA201071045A1 (ru) 2011-02-28
AU2009221722A1 (en) 2009-09-11
WO2009111700A3 (en) 2010-03-04
CA2716664A1 (en) 2009-09-11
EP2262364A4 (en) 2012-04-04
CN101959405B (zh) 2014-07-02
ES2567451T3 (es) 2016-04-22
CA2716664C (en) 2016-10-11
WO2009111700A2 (en) 2009-09-11
BRPI0910282A2 (pt) 2015-09-01
US20100197677A1 (en) 2010-08-05
US20140187769A1 (en) 2014-07-03
US20130317015A1 (en) 2013-11-28
NZ587343A (en) 2012-05-25
JP5382952B2 (ja) 2014-01-08
MA32175B1 (fr) 2011-03-01
EP2262364A2 (en) 2010-12-22
KR20100131455A (ko) 2010-12-15
US7906507B2 (en) 2011-03-15
ZA201006367B (en) 2011-05-25
KR101616737B1 (ko) 2016-05-02
US20110039837A1 (en) 2011-02-17
US7727983B2 (en) 2010-06-01
EP2262364B1 (en) 2016-03-02
CN101959405A (zh) 2011-01-26
IL207570A (en) 2014-03-31
US20150087640A1 (en) 2015-03-26
MX2010009752A (es) 2010-09-30
US8524708B2 (en) 2013-09-03
DK2262364T3 (en) 2016-03-21
US8703766B2 (en) 2014-04-22
AU2009221722B2 (en) 2014-12-18
JP2011513431A (ja) 2011-04-28
EA018225B1 (ru) 2013-06-28
US9120813B2 (en) 2015-09-01
US20100324033A1 (en) 2010-12-23
IL207570A0 (en) 2010-12-30
US20090306063A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
HK1148435A1 (en) Oxadiazoanthracene compounds for the treatment of diabetes
IL259475A (en) Combined therapy for the treatment of diabetes
ZA200902374B (en) Compositions useful for the treatment of diabetes
ZA201105720B (en) Compounds for the treatment of hepatitis c
PL2303021T3 (pl) Związki do leczenia nowotworu
EP2320907A4 (en) THERAPEUTIC COMPOUNDS
ZA200906129B (en) Compounds for the treatment of hepatitis c
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
EP2268285A4 (en) THERAPEUTIC COMPOUNDS
GB0806794D0 (en) Therapeutic compounds
PL2209784T3 (pl) Związki do leczenia zapalenia wątroby typu C
ZA201000923B (en) Compounds for the treatment of hepatitis c
GB0813740D0 (en) Therapeutic compounds
GB0804755D0 (en) Therapeutic compounds
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
EP2358200A4 (en) BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
IL211267A0 (en) Oxadiazole derivatives for the treatment of diabetes
EP2331099A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS
GB0819536D0 (en) Compounds for the treatment of neoplasia
GB0817857D0 (en) Compounds for the treatment of neoplasia
GB0802903D0 (en) Treatment of diabetes
GB0814997D0 (en) Processes for the preparation of compounds
GB0809319D0 (en) The treatment of puritus
GB0811850D0 (en) Therapeutic compounds
GB0815700D0 (en) Therapeutic compounds